WHO ICTRP trial
Discontinuation of antidementia medication in extremely severe dementia…
KCT0000874 · Clinical Research Information Service (CRIS) · Recruiting
Key facts
| Trial ID | KCT0000874 |
|---|---|
| Public title | Discontinuation of antidementia medication in extremely severe dementia patients: a 12-week randomized multicenter trial |
| Scientific title | Discontinuation of Donepezil or Memantine in Extremely Severe Alzheimer`s Disease Patients : A 12-Week, Randomized, Multi-center Trial |
| Primary sponsor | Bobath Memorial Hospital |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Recruiting |
| Study type | Interventional Study |
| Phase | Phase4 |
| Countries | Korea, Republic of |
| Conditions | Diseases of the nervous system |
| Interventions | Drug : Stop donepezil (5/10mg) or memantine (10/20mg) treatment for 3 months in Alzheimer's disease and compare the outcome variables between discontinuation group and continuation group |
| Registration date | Oct 8, 2013 |
| Target size | 120 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: